Cytokinetics announces full Phase III data for aficamten

14 May 2024

Shares of US biotech Cytokinetics (Nasdaq: CYTK) fell 6.6% to $57.96 by late morning yesterday, after it announced new data on its heart drug aficamten.

Cytokinetics released what it called “positive detailed results” from SEQUOIA-HCM, the pivotal Phase III clinical trial evaluating the company’s investigational next-in-class cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy (oHCM), a chronic and progressive disease of the heart muscle that can lead to heart failure.

Results were presented in three late breaking presentations at Heart Failure 2024, an International Congress of the European Society of Cardiology, and the primary results were simultaneously published in the New England Journal of Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK